News | Leaps by Bayer

Latest news,
from us and our partners

Are you a media representative (journalist, blogger, etc.) and would like more information about Leaps by Bayer? Feel free to get in touch with Kira Peikoff. Do you have any queries or comments? Please use the links to the relevant contact forms.

Venture announcements

May 2023

Boundless Bio Announces $100 Million Series C Financing co-led by Leaps by Bayer and RA Capital Management to Advance First ecDNA-Directed Therapies for Patients with Oncogene Amplified Cancer

ChrysaLabs Secures CA $15 Million ($11 Million) Series A Funding to Increase Instant Access to Reliable and Low-Cost Soil Insights, Including Carbon Verification

What can bats, naked mole rats and Jaws tell us about human biology? Paratus is on a $100M mission to find out

NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs

AskBio Announces Strategic Collaboration with ReCode Therapeutics to Explore Single Vector Gene Editing Platform

Leaps by Bayer leads investment round in AgTech pioneer NuCicer to bring unique and cost-effective plant-protein ingredients to market by 2023

Capstan Therapeutics Launches with $165 Million to Deliver on the Clinical Promise of Precise In Vivo Cell Engineering

Bayer expands existing investment to acquire majority share in sustainable lower carbon oilseed producer CoverCress Inc.

More News

June 2022

ReCode Therapeutics to Expand Next-Generation Delivery Platform and Diversify Genetic Medicines Pipeline with Oversubscribed Series B Financing Totaling $200M

Woebot Health Secures $9.5 Million Investment From Leaps by Bayer

Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations

Indapta Therapeutics Names Mark W. Frohlich, M.D., Chief Executive Officer and Raises Over $50 Million in Series A Financing and Commitments to Advance Development of G-NK Cell Therapy to Treat Multiple Types of Cancer

Gandeeva Raises $40M in Series A Funding to Develop Novel Therapies Based on Precision Imaging of Protein-Drug Interactions

Leaps by Bayer leads $80M Series A Financing for Cellino Biotech to Autonomize Stem Cell Therapy Manufacturing

Bloom Science Raises USD $12 Million in Series A Financing

GRO Biosciences Announces $25M Series A Financing Led by Leaps by Bayer and Redmile Group

Deka Biosciences Raises USD 20 Million in Series A Financing

Immunitas Therapeutics Launches with $39 Million to Advance Lead Programs to Human Efficacy Studies Based on a Unique Immunology-Focused Drug Development Platform

Mozart Therapeutics Launches with $55 Million Series A Financing to Develop Disease Modifying Therapeutics for Autoimmune and Inflammatory Diseases

EarthOptics Raises $10.3 million in Series A Funding, Led by Leaps by Bayer, to Accelerate Carbon Mapping

Andes raises USD 15 million in Series A funding co-led by Leaps by Bayer and Cavallo Ventures

Leaps by Bayer Leads USD 45 Million Financing in Sound Agriculture to Accelerate Sustainability Solutions for Food and Agriculture

Kojin Therapeutics Launches with $60 Million Series A to Develop New Category of Drugs Based on Cell State Biology

Leaps by Bayer leads USD 90 Million Series B financing in digital health company Ada Health

Edifice, a Healthcare Disruptor spun out of Stanford, Raises $12 Million to Reinvent Immune Health, Improve Healthspan, and Change Course of Aging

Guardian Agriculture Launches With $10.5 Million Financing to Modernize Crop Protection With eVTOL-Powered Precision

Amfora Raises $6 Million with Investment from Leaps by Bayer and Spruce Capital Partners

Leaps by Bayer leads Series B financing in Senti Bio to develop next-generation cell and gene therapies using advanced gene circuit technology platform

Ukko secures USD 40 million in Series B funding led by Leaps by Bayer to overcome food allergies and sensitivities

Bayer backs drone spraying platform Rantizo in $7.5m Series A round

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

Leaps by Bayer leads USD 17 million Series B financing in biotech company Azitra

Bayer collaborates with Recursion to strengthen efforts in digital drug discovery and advance new therapies for fibrotic diseases.

Bayer and Northpond Ventures lead 55 million Series A financing round for Triumvira Immunologics

Bayer and Temasek unveil innovative new company focused on developing breakthroughs in vertical farming

Biotech incubator FutuRx announces new investor Leaps by Bayer

NewLeaf Symbiotics raises $20m Series D to expand offerings to broadacre row crops

Vesigen Therapeutics launches with USD 28.5 million Series A investment led by Leaps by Bayer and Morningside Ventures

Leaps by Bayer stands among 20+ biopharma leaders to launch the AMR Action Fund in the fight against antimicrobial resistance

Leaps by Bayer invests in Series A funding of Apollo Agriculture, a Nairobi-based startup helping small scale farmers maximize their crops to build a sustainable food supply

Bayer invests USD 50 Million in eGenesis Series B financing round

CRISPR Therapeutics and Bayer Announce an Update on Casebia Therapeutics

Bayer and Informed Data Systems Inc. to develop One Drop digital therapeutics platform for multiple therapeutic areas

Pyxis Oncology Founded by Longwood Fund with Financing Led by Bayer

Bayer acquires BlueRock Therapeutics to build leading position in cell therapy

Century Therapeutics launches with USD 250M financing for induced pluripotent stem cell (iPSC) allogeneic cell therapy platform

Bayer and Arvinas to Collaborate on Human PROTAC® Therapies

Leaps by Bayer and Khloris join forces to develop induced pluripotent stem cells (iPSCs) as breakthrough anti-cancer vaccines

Dewpoint Therapeutics Launches with $60 Million Series A to Advance Proprietary Platform for Drugging Condensates

Bayer wagt sich mit Leaps an die irren Fragen der Biotechnologie

Bayer and Ginkgo Bioworks join forces for sustainable agriculture, forming new company with USD 100 million Series A

Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing

Leaps news

January 2023

Leaps by Bayer Annual Review 2022

Leaps by Bayer Annual Review 2021

Leaping forward: Bayer VC arm commits $1.4B to double investment pace through 2024

In biopharma VC world, what does it mean to take a 'leap'? For Leaps by Bayer, it's 'fewer, but maybe bigger bets'

Taking a leap in sustainable innovation

The world has a big fertiliser problem. Here’s how to fix it

More News

July 2021

The six types of CVCs — and how to pick the best one for your company

The biorevolution is kicking off. Here's how to harness its opportunities early on

Inside the Bio Revolution

Leaps by Bayer on adopting an impact lens for corporate venturing

Innovation in health and agriculture. We need to think bigger

Bayer Uses Famous Skateboard Leap to Launch New Initiative

Vorhang auf für Leaps by Bayer

Leaps thought-leadership

November 2023

Nobel Winner Drew Weissman Shares 7 Insights On Future mRNA Breakthroughs

Why The Next Blockbuster Therapy May Come Out Of Singapore

AI Chatbots—With Careful Guardrails—Can Help Treat Depression And Anxiety

The Gut Microbiome May Unlock New Treatment Paradigms For Neurological Diseases

Phage Therapy To Defeat Superbugs Is Taking Off

Novel Approaches To Treat Parkinson’s Disease May Signal A Turning Point

The Critical Fix We Need To Rebuild Our Broken Antibiotic Pipeline

A New Tomato And A Potential New Class Of Medicine Share This Fascinating Technology

Cell Therapy Is Poised To Break Through, If We Solve These Hurdles Now

Interview with Werner Baumann — CEO of Bayer AG and responsible Board of Management member for Leaps by Bayer since January 2020

Planting the seeds of a greener future

How can AI improve human health?

Looking Back on 2022: A Year of Milestones Amid Challenging Times

New paradigms for an ancient disease

Chapter III: Leap Forward: Breaking through impossible. Together.

Why impact investing matters

Distributed agtech to build a stable food supply

Sustainable Protein to Nourish a Growing World

Protecting our brains and minds

Manufacturing Cell Therapies at Scale to Cure Disease

Could the Bio Revolution Restore Balance to Immune Systems That Turn Against Our Bodies?

2021 in Review: A Challenging and Inspiring Year

Teaming up With Soil Microbes to Fight Climate change

On Updating our 10 Leaps

Leveraging Big Data to Transform Patient Health

New Frontiers in Cell and Gene Therapy

Hacking Our Immune Systems for Good

10 Leaps for Humanity and Why They Matter

Big Biotech Breakthrough Opportunities in Agriculture to Watch in 2021 and Beyond

Big Biotech Breakthrough Opportunities in Healthcare to Watch in 2021 and Beyond

Metagenomi — Where AI, Biology and Big Data Converge to Discover New Gene Editing Tools

The Magic, Power, and Impact of iPSCs

Vertical Farming’s Missing Link

Latest news, from us and our partners

Venture announcements

May 2023

Boundless Bio Announces $100 Million Series C Financing co-led by Leaps by Bayer and RA Capital Management to Advance First ecDNA-Directed Therapies for Patients with Oncogene Amplified Cancer

May 2023

ChrysaLabs Secures CA $15 Million ($11 Million) Series A Funding to Increase Instant Access to Reliable and Low-Cost Soil Insights, Including Carbon Verification

February 2023

What can bats, naked mole rats and Jaws tell us about human biology? Paratus is on a $100M mission to find out

January 2023

NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs

January 2023

AskBio Announces Strategic Collaboration with ReCode Therapeutics to Explore Single Vector Gene Editing Platform

October 2022

Leaps by Bayer leads investment round in AgTech pioneer NuCicer to bring unique and cost-effective plant-protein ingredients to market by 2023

September 2022

Capstan Therapeutics Launches with $165 Million to Deliver on the Clinical Promise of Precise In Vivo Cell Engineering

August 2022

Bayer expands existing investment to acquire majority share in sustainable lower carbon oilseed producer CoverCress Inc.

June 2022

ReCode Therapeutics to Expand Next-Generation Delivery Platform and Diversify Genetic Medicines Pipeline with Oversubscribed Series B Financing Totaling $200M

March 2022

Woebot Health Secures $9.5 Million Investment From Leaps by Bayer

March 2022

Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations

February 2022

Indapta Therapeutics Names Mark W. Frohlich, M.D., Chief Executive Officer and Raises Over $50 Million in Series A Financing and Commitments to Advance Development of G-NK Cell Therapy to Treat Multiple Types of Cancer

January 2022

Gandeeva Raises $40M in Series A Funding to Develop Novel Therapies Based on Precision Imaging of Protein-Drug Interactions

January 2022

Leaps by Bayer leads $80M Series A Financing for Cellino Biotech to Autonomize Stem Cell Therapy Manufacturing

December 2021

Bloom Science Raises USD $12 Million in Series A Financing

November 2021

GRO Biosciences Announces $25M Series A Financing Led by Leaps by Bayer and Redmile Group

November 2021

Deka Biosciences Raises USD 20 Million in Series A Financing

November 2021

Immunitas Therapeutics Launches with $39 Million to Advance Lead Programs to Human Efficacy Studies Based on a Unique Immunology-Focused Drug Development Platform

October 2021

Mozart Therapeutics Launches with $55 Million Series A Financing to Develop Disease Modifying Therapeutics for Autoimmune and Inflammatory Diseases

September 2021

EarthOptics Raises $10.3 million in Series A Funding, Led by Leaps by Bayer, to Accelerate Carbon Mapping

September 2021

Andes raises USD 15 million in Series A funding co-led by Leaps by Bayer and Cavallo Ventures

August 2021

Leaps by Bayer Leads USD 45 Million Financing in Sound Agriculture to Accelerate Sustainability Solutions for Food and Agriculture

June 2021

Kojin Therapeutics Launches with $60 Million Series A to Develop New Category of Drugs Based on Cell State Biology

May 2021

Leaps by Bayer leads USD 90 Million Series B financing in digital health company Ada Health

April 2021

Edifice, a Healthcare Disruptor spun out of Stanford, Raises $12 Million to Reinvent Immune Health, Improve Healthspan, and Change Course of Aging

April 2021

Guardian Agriculture Launches With $10.5 Million Financing to Modernize Crop Protection With eVTOL-Powered Precision

March 2021

Amfora Raises $6 Million with Investment from Leaps by Bayer and Spruce Capital Partners

January 2021

Leaps by Bayer leads Series B financing in Senti Bio to develop next-generation cell and gene therapies using advanced gene circuit technology platform

January 2021

Ukko secures USD 40 million in Series B funding led by Leaps by Bayer to overcome food allergies and sensitivities

December 2020

Bayer backs drone spraying platform Rantizo in $7.5m Series A round

November 2020

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

October 2020

Leaps by Bayer leads USD 17 million Series B financing in biotech company Azitra

September 2020

Bayer collaborates with Recursion to strengthen efforts in digital drug discovery and advance new therapies for fibrotic diseases.

August 2020

Bayer and Northpond Ventures lead 55 million Series A financing round for Triumvira Immunologics

August 2020

Bayer and Temasek unveil innovative new company focused on developing breakthroughs in vertical farming

July 2020

Biotech incubator FutuRx announces new investor Leaps by Bayer

February 2020

NewLeaf Symbiotics raises $20m Series D to expand offerings to broadacre row crops

July 2020

Vesigen Therapeutics launches with USD 28.5 million Series A investment led by Leaps by Bayer and Morningside Ventures

July 2020

Leaps by Bayer stands among 20+ biopharma leaders to launch the AMR Action Fund in the fight against antimicrobial resistance

Latest news,
from us and our partners